Nyxoah GmbH

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution platform is based on the Genio® system, an FDA approved and CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke. Learn more about Genio , an alternative treatment for obstructive sleep apnea developed by Nyxoah for people who cannot tolerate, have failed or refused CPAP therapy.